報價延遲最少15分鐘:2025/05/31 15:57 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.3125 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.06/--
|
|
企業價值
11.84M
|
| 資產負債 |
|
每股賬面淨值
0.96
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/31 15:57 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system. |